Dr. Tabernero is a physician-scientist who conducts laboratory and clinical research in the field of gastrointestinal tumors with particular focus in early drug development.He is currently Head of the Medical Oncology Department at the Vall d'Hebron Barcelona Hospital Campus, Director of the Vall d'Hebron Institute of Oncology, and leads the Research Innovation of Catalonian Cancer Centers Network.He specializes in the development of molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation.He is actively involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies and related translational research.He has been elected ESMO President 2018-2019 and serves as President-Elect from 2016.He is also a well-appreciated international lecturer having been invited to 150 lectures in 15 years.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Vall d'Hebron Institute of Oncology
Servier and Taiho Pharmaceutical Co., Ltd. today announced clinical data from the pivotal Phase III trial for LONSURF® which showed significant improvement in overall survival for the treatment of patients with refractory metastatic gastric cancer . The overall safety profile was consistent with the known safety profile of trifluridine/tipiracil in metastatic colorectal cancer, with mainly hematological adverse events reported. "The results presented today from TAGS demonstrate the potential of trifluridine/tipiracil in this group of patients with late-stage metastatic gastric cancer", said Professor Josep Tabernero. TAGS enrolled 507 adult patients with metastatic gastric cancer who had previously received at least two prior regimens for advanced disease.